Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Janux Therapeutics Inc.

    NASDAQ: JANX · Real-Time Price · USD
    23.34
    0.24 (1.04%)
    At close: Jul 01, 2025, 1:10 PM

    Janux Therapeutics Statistics

    Share Statistics

    Janux Therapeutics has 59.18M shares outstanding. The number of shares has increased by 13.44% in one year.

    Shares Outstanding

    n/a
    		 59.18M

    Shares Change (YoY)

    n/a
    		 13.44%

    Shares Change (QoQ)

    n/a
    		 0.12%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 49.54M

    Failed to Deliver (FTD) Shares

    n/a
    		 5

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 10.61M, so 17.93% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 10.61M

    Short % of Shares Out

    n/a
    		 17.93%

    Short % of Float

    n/a
    		 25.94%

    Short Ratio (days to cover)

    n/a
    		 17.8

    Valuation Ratios

    The PE ratio is -41.71 and the forward PE ratio is -9.14. Janux Therapeutics's PEG ratio is 13.76.

    PE Ratio

    n/a
    		 -41.71

    Forward PE

    n/a
    		 -9.14

    PS Ratio

    n/a
    		 271.8

    Forward PS

    n/a
    		 4.2

    PB Ratio

    n/a
    		 2.81

    P/FCF Ratio

    n/a
    		 -65.15

    PEG Ratio

    n/a
    		 13.76
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Janux Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 59.21, with a Debt / Equity ratio of 0.02.

    Current Ratio

    n/a
    		 59.21

    Quick Ratio

    n/a
    		 59.21

    Debt / Equity

    n/a
    		 0.02

    Debt / EBITDA

    n/a
    		 -0.23

    Debt / FCF

    n/a
    		 -0.52

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $116,351.65

    Profits Per Employee

    n/a
    		 $-758,175.82

    Employee Count

    n/a
    		 91

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -44.56% in the last 52 weeks. The beta is 2.96, so Janux Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.96

    52-Week Price Change

    n/a
    		 -44.56%

    50-Day Moving Average

    n/a
    		 26.17

    200-Day Moving Average

    n/a
    		 39.77

    Relative Strength Index (RSI)

    n/a
    		 40.81

    Average Volume (20 Days)

    n/a
    		 984,175

    Income Statement

    In the last 12 months, Janux Therapeutics had revenue of 10.59M and earned -68.99M in profits. Earnings per share was -1.28.

    Revenue

    n/a
    		 10.59M

    Gross Profit

    n/a
    		 8.53M

    Operating Income

    n/a
    		 -98.85M

    Net Income

    n/a
    		 -68.99M

    EBITDA

    n/a
    		 -98.85M

    EBIT

    n/a
    		 -98.85M

    Earnings Per Share (EPS)

    n/a
    		 -1.28
    Full Income Statement

    Balance Sheet

    The company has 430.61M in cash and 23.02M in debt, giving a net cash position of 407.58M.

    Cash & Cash Equivalents

    n/a
    		 430.61M

    Total Debt

    n/a
    		 23.02M

    Net Cash

    n/a
    		 407.58M

    Retained Earnings

    n/a
    		 -237.76M

    Total Assets

    n/a
    		 1.05B

    Working Capital

    n/a
    		 1.01B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -43.81M and capital expenditures -359K, giving a free cash flow of -44.17M.

    Operating Cash Flow

    n/a
    		 -43.81M

    Capital Expenditures

    n/a
    		 -359K

    Free Cash Flow

    n/a
    		 -44.17M

    FCF Per Share

    n/a
    		 -0.82
    Full Cash Flow Statement

    Margins

    Gross margin is 80.54%, with operating and profit margins of -933.58% and -651.62%.

    Gross Margin

    n/a
    		 80.54%

    Operating Margin

    n/a
    		 -933.58%

    Pretax Margin

    n/a
    		 -651.62%

    Profit Margin

    n/a
    		 -651.62%

    EBITDA Margin

    n/a
    		 -933.58%

    EBIT Margin

    n/a
    		 -933.58%

    FCF Margin

    n/a
    		 -417.2%

    Dividends & Yields

    JANX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for JANX is $72, which is 211.3% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $72

    Price Target Difference

    n/a
    		 211.3%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 22.65

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist